Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment

被引：13
作者：
Gevaert, Thomas [1 ,2 ]
Montironi, Rodolfo [3 ]
Lopez-Beltran, Antonio [4 ,5 ]
Van Leenders, Geert [6 ]
Allory, Yves [7 ]
De Ridder, Dirk [8 ]
Claessens, Frank [9 ]
Kockx, Mark [10 ]
Akand, Murat [11 ]
Joniau, Steven [8 ]
Netto, George [12 ]
Libbrecht, Louis [13 ]
机构：
[1] Katholieke Univ Leuven, Lab Expt Urol, Organ Syst, Leuven, Belgium
[2] AZ Klina, Dept Pathol, Brasschaat, Belgium
[3] Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, Ancona, Italy
[4] Fac Med, Dept Surg & Pathol, Anat Pathol Unit, Cordoba, Spain
[5] Champalimaud Clin Ctr, Lisbon, Portugal
[6] Erasmus Univ, Med Ctr, Dept Pathol, Rotterdam, Netherlands
[7] Univ Paris Est Creteil Val de Marne UPEC, Hop Henri Mondor, Fac Med, Serv Anat Pathol, Creteil, France
[8] Univ Hosp Leuven, Dept Urol, Leuven, Belgium
[9] Katholieke Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Leuven, Belgium
[10] HistoGeneX, Dept Mol Pathol, Antwerp, Belgium
[11] Selcuk Univ, Sch Med, Dept Urol, Konya, Turkey
[12] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[13] Univ Clin St Luc, Dept Pathol, Sint Lambrechts Woluwe, Belgium
来源：
SEMINARS IN CANCER BIOLOGY | 2018年 / 52卷
关键词：
Immunotherapy; Bladder; Kidney; Prostate; Biomarkers; RENAL-CELL CARCINOMA; RESISTANT PROSTATE-CANCER; MISMATCH REPAIR GENES; METASTATIC UROTHELIAL CARCINOMA; INVASIVE BLADDER-CANCER; UPPER URINARY-TRACT; IMMUNE CHECKPOINT INHIBITORS; CISPLATIN-BASED CHEMOTHERAPY; LYNCH SYNDROME; ANDROGEN RECEPTOR;
D O I：
10.1016/j.semcancer.2017.10.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers. Based on cancer incidences and available data we restricted this overview to bladder, prostate and renal cancer.
引用
收藏
页码：216 / 227
页数：12
相关论文
共 177 条
  • [101] Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma
    Lindgren, David
    Sjodahl, Gottfrid
    Lauss, Martin
    Staaf, Johan
    Chebil, Gunilla
    Lovgren, Kristina
    Gudjonsson, Sigurdur
    Liedberg, Fredrik
    Patschan, Oliver
    Mansson, Wiking
    Ferno, Marten
    Hoglund, Mattias
    [J]. PLOS ONE, 2012, 7 (06):
  • [102] Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
    Linehan, W. Marston
    Spellman, Paul T.
    Ricketts, Christopher J.
    Creighton, Chad J.
    Fei, Suzanne S.
    Davis, Caleb
    Wheeler, David A.
    Murray, Bradley A.
    Schmidt, Laura
    Vocke, Cathy D.
    Peto, Myron
    Al Mamun, Abu Amar M.
    Shinbrot, Eve
    Sethi, Anurag
    Brooks, Samira
    Rathmell, W. Kimryn
    Brooks, Angela N.
    Hoadley, Katherine A.
    Robertson, A. Gordon
    Brooks, Denise
    Bowlby, Reanne
    Sadeghi, Sara
    Shen, Hui
    Weisenberger, Daniel J.
    Bootwalla, Moiz
    Baylin, Stephen B.
    Laird, Peter W.
    Cherniack, Andrew D.
    Saksena, Gordon
    Haake, Scott
    Li, Jun
    Liang, Han
    Lu, Yiling
    Mills, Gordon B.
    Akbani, Rehan
    Leiserson, Mark D. M.
    Raphael, Benjamin J.
    Anur, Pavana
    Bottaro, Donald
    Albiges, Laurence
    Barnabas, Nandita
    Choueiri, Toni K.
    Czerniak, Bogdan
    Godwin, Andrew K.
    Hakimi, A. Ari
    Ho, Thai H.
    Hsieh, James
    Ittmann, Michael
    Kim, William Y.
    Krishnan, Bhavani
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (02) : 135 - 145
  • [103] Alterations of androgen receptor in prostate cancer
    Linja, MJ
    Visakorpi, T
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 92 (04) : 255 - 264
  • [104] The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
    Llosa, Nicolas J.
    Cruise, Michael
    Tam, Ada
    Wicks, Elizabeth C.
    Hechenbleikner, Elizabeth M.
    Taube, Janis M.
    Blosser, Richard L.
    Fan, Hongni
    Wang, Hao
    Luber, Brandon S.
    Zhang, Ming
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Sears, Cynthia L.
    Anders, Robert A.
    Pardoll, Drew M.
    Housseau, Franck
    [J]. CANCER DISCOVERY, 2015, 5 (01) : 43 - 51
  • [105] Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Madan, Ravi A.
    Mohebtash, Mahsa
    Arlen, Philip M.
    Vergati, Matteo
    Rauckhorst, Myrna
    Steinberg, Seth M.
    Tsang, Kwong Y.
    Poole, Diane J.
    Parnes, Howard L.
    Wright, John J.
    Dahut, William L.
    Schlom, Jeffrey
    Gulley, James L.
    [J]. LANCET ONCOLOGY, 2012, 13 (05) : 501 - 508
  • [106] Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
    Mann, Steven A.
    Lopez-Beltran, Antonio
    Massari, Francesco
    Pili, Roberto
    Fiorentino, Michelangelo
    Koch, Michael O.
    Kaimakliotis, Hristos Z.
    Wang, Lisha
    Scarpelli, Marina
    Ciccarese, Chiara
    Moch, Holger
    Montironi, Rodolfo
    Cheng, Liang
    [J]. CURRENT DRUG METABOLISM, 2017, 18 (08) : 700 - 711
  • [107] Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
    Martin, A. M.
    Nirschl, T. R.
    Nirschl, C. J.
    Francica, B. J.
    Kochel, C. M.
    Van Bokhoven, A.
    Meeker, A. K.
    Lucia, M. S.
    Anders, R. A.
    DeMarzo, A. M.
    Drake, C. G.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (04) : 325 - 332
  • [108] Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
    Massard, Christophe
    Gordon, Michael S.
    Sharma, Sunil
    Rafii, Saeed
    Wainberg, Zev A.
    Luke, Jason
    Curiel, Tyler J.
    Colon-Otero, Gerardo
    Hamid, Omid
    Sanborn, Rachel E.
    O'Donnell, Peter H.
    Drakaki, Alexandra
    Tan, Winston
    Kurland, John F.
    Rebelatto, Marlon C.
    Jin, Xiaoping
    Blake-Haskins, John A.
    Gupta, Ashok
    Segal, Neil H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26) : 3119 - +
  • [109] Nivolumab in renal cell carcinoma: latest evidence and clinical potential
    Mazza, Camille
    Escudier, Bernard
    Albiges, Laurence
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (03) : 171 - 181
  • [110] A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer
    McConkey, David J.
    Choi, Woonyoung
    Shen, Yu
    Lee, I. -Ling
    Porten, Sima
    Matin, Surena F.
    Kamat, Ashish M.
    Corn, Paul
    Millikan, Randall E.
    Dinney, Colin
    Czerniak, Bogdan
    Siefker-Radtke, Arlene O.
    [J]. EUROPEAN UROLOGY, 2016, 69 (05) : 855 - 862
6789101112131415